Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/
THE U.S. DISTRICT COURT HAS ISSUED A DECISION IN OUR FAVOR IN OUR U.S. PATENT LITIGATION REGARDING BENICAR(R), BENICAR HCT(R) AND AZOR®
TOKYO, Japan (August 3, 2009)－ Daiichi Sankyo Company, Limited announced today that the U.S. District Court in New Jersey has issued a decision in our U.S. patent litigation against Mylan* upholding the validity of our patent covering the Benicar®, Benicar HCT® and AZOR® products. We had initiated the litigation against Mylan in response to Abbreviated New Drug Applications ("ANDAs") filed by Mylan seeking to market generic versions of those products before the expiration of our patent, which expires in 2016.
Olmesartan medoxomil, an active ingredient in Benicar®, Benicar HCT® and AZOR®, is an angiotensin II receptor antagonist that Daiichi Sankyo independently developed, and is marketed in over 50 countries as an antihypertensive drug which suppresses vasoconstriction by affecting the rennin-angiotensin system to control blood pressure.
*Note:
"Mylan" refers to Mylan Inc. (HQ: Pennsylvania) and Matrix Laboratories, Limited (HQ: India), a subsidiary of Mylan.
